دورية أكاديمية
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial
| العنوان: | HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial |
|---|---|
| المؤلفون: | Ensoli, Fabrizio, Cafaro, Aurelio, CASABIANCA, ANNA, Tripiciano, Antonella, Bellino, Stefania, Longo, Olimpia, Francavilla, Vittorio, Picconi, Orietta, Sgadari, Cecilia, Moretti, Sonia, Cossut, Maria R. Pavone, Arancio, Angela, ORLANDI, CHIARA, Sernicola, Leonardo, Maggiorella, Maria T, Paniccia, Giovanni, Mussini, Cristina, Lazzarin, Adriano, Sighinolfi, Laura, Palamara, Guido, Gori, Andrea, Angarano, Gioacchino, Di Pietro, Massimo, Galli, Massimo, Mercurio, Vito S, Castelli, Francesco, Di Perri, Giovanni, Monini, Paolo, MAGNANI, MAURO, Garaci, Enrico, Ensoli, Barbara |
| المساهمون: | Ensoli, Fabrizio, Cafaro, Aurelio, Casabianca, Anna, Tripiciano, Antonella, Bellino, Stefania, Longo, Olimpia, Francavilla, Vittorio, Picconi, Orietta, Sgadari, Cecilia, Moretti, Sonia, Cossut, Maria R. Pavone, Arancio, Angela, Orlandi, Chiara, Sernicola, Leonardo, Maggiorella, Maria T, Paniccia, Giovanni, Mussini, Cristina, Lazzarin, Adriano, Sighinolfi, Laura, Palamara, Guido, Gori, Andrea, Angarano, Gioacchino, Di Pietro, Massimo, Galli, Massimo, Mercurio, Vito S, Castelli, Francesco, Di Perri, Giovanni, Monini, Paolo, Magnani, Mauro, Garaci, Enrico, Ensoli, Barbara |
| سنة النشر: | 2015 |
| المجموعة: | Università degli Studi di Urbino: CINECA IRIS |
| مصطلحات موضوعية: | AIDS Vaccine, Acquired Immunodeficiency Syndrome, Adult, Antibodies, Neutralizing, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Female, Follow-Up Studie, HIV Antibodie, Human, Immunoglobulin G, Immunoglobulin M, Italy, Leukocyte, Male, Middle Aged, Treatment Outcome, Young Adult, tat Gene Products, Human Immunodeficiency Viru, Viral Load |
| الوصف: | The phase II multicenter, randomized, open label, therapeutic trial (ISS T-002, Clinicaltrials.gov NCT00751595) was aimed at evaluating the immunogenicity and the safety of the biologically active HIV-1 Tat protein administered at 7.5 or 30 μg, given 3 or 5 times monthly, and at exploring immunological and virological disease biomarkers. The study duration was 48 weeks, however, vaccinees were followed until the last enrolled subject reached the 48 weeks. Reported are final data up to 144 weeks of follow-up. The ISS T-002 trial was conducted in 11 clinical centers in Italy on 168 HIV positive subjects under Highly Active Antiretroviral Therapy (HAART), anti-Tat Antibody (Ab) negative at baseline, with plasma viremia <50 copies/mL in the last 6 months prior to enrollment, and CD4(+) T-cell number ≥200 cells/μL. Subjects from a parallel observational study (ISS OBS T-002, Clinicaltrials.gov NCT0102455) enrolled at the same clinical sites with the same criteria constituted an external reference group to explore biomarkers of disease. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/wos/WOS:000353539300001; volume:12; issue:1; firstpage:12; lastpage:33; numberofpages:28; journal:RETROVIROLOGY; http://hdl.handle.net/11576/2638934Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84928563445 |
| DOI: | 10.1186/s12977-015-0151-y |
| الإتاحة: | https://doi.org/10.1186/s12977-015-0151-yTest http://hdl.handle.net/11576/2638934Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.D313D9ED |
| قاعدة البيانات: | BASE |
| DOI: | 10.1186/s12977-015-0151-y |
|---|